Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron today and set a price target of $1,057.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Newman covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Nuvalent, and Regeneron. According to TipRanks, Newman has an average return of 2.8% and a 42.37% success rate on recommended stocks.
In addition to Canaccord Genuity, Regeneron also received a Buy from Piper Sandler’s Biren Amin in a report issued today. However, yesterday, Scotiabank maintained a Hold rating on Regeneron (NASDAQ: REGN).
Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million
Read More on REGN:
Disclaimer & DisclosureReport an Issue
- Regeneron announces agreement with U.S. government to help lower drug costs
- FDA grants accelerated approval for Regeneron’s Otarmeni
- Regeneron agrees to lower prices as gene therapy approved, Bloomberg says
- Regeneron price target raised to $960 from $880 at TD Cowen
- Regeneron, Sanofi: FDA approves Dupixent for treatment of CSU in ages 2-11
